NDM Research Building, University of Oxford, Old Road Campus, Oxford, UK.
Department of Biochemistry, Faculty of Science, Center of Innovation in Personalized Medicine, King Fahd Center for Medical Research, King Abdulaziz University, Jeddah, Saudi Arabia.
Life Sci Alliance. 2023 Feb 1;6(4). doi: 10.26508/lsa.202201756. Print 2023 Apr.
Hypoxia-inducible factor (HIF) and aryl hydrocarbon receptor (AHR) are members of the bHLH-PAS family of transcription factors that underpin cellular responses to oxygen and to endogenous and exogenous ligands, respectively, and have central roles in the pathogenesis of renal cancer. Composed of heterodimers, they share a common HIF-1β/ARNT subunit and similar DNA-binding motifs, raising the possibility of crosstalk between the two transcriptional pathways. Here, we identify both general and locus-specific mechanisms of interaction between HIF and AHR that act both antagonistically and cooperatively. Specifically, we observe competition for the common HIF-1β/ARNT subunit, in cis synergy for chromatin binding, and overlap in their transcriptional targets. Recently, both HIF and AHR inhibitors have been developed for the treatment of solid tumours. However, inhibition of one pathway may promote the oncogenic effects of the other. Therefore, our work raises important questions as to whether combination therapy targeting both of these pro-tumourigenic pathways might show greater efficacy than targeting each system independently.
缺氧诱导因子 (HIF) 和芳香烃受体 (AHR) 是 bHLH-PAS 转录因子家族的成员,分别为细胞对氧气和内源性及外源性配体的反应提供基础,并在肾癌的发病机制中发挥核心作用。它们由异二聚体组成,共享一个共同的 HIF-1β/ARNT 亚基和相似的 DNA 结合基序,这增加了两种转录途径之间串扰的可能性。在这里,我们确定了 HIF 和 AHR 之间相互作用的一般和特定基因座机制,这些机制既具有拮抗作用,也具有协同作用。具体而言,我们观察到共同的 HIF-1β/ARNT 亚基的竞争、染色质结合的顺式协同作用以及转录靶标的重叠。最近,已经开发出了用于治疗实体瘤的 HIF 和 AHR 抑制剂。然而,抑制一种途径可能会促进另一种途径的致癌作用。因此,我们的工作提出了一个重要的问题,即针对这两种促肿瘤发生途径的联合治疗是否可能比单独针对每个系统更有效。